Universal Beteiligungs und Servicegesellschaft mbH Has $25.50 Million Stock Holdings in ResMed Inc. $RMD

Universal Beteiligungs und Servicegesellschaft mbH lifted its holdings in ResMed Inc. (NYSE:RMD) by 6.1% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 105,621 shares of the medical equipment provider’s stock after buying an additional 6,095 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in ResMed were worth $25,499,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. SJS Investment Consulting Inc. grew its holdings in ResMed by 1,433.3% during the 3rd quarter. SJS Investment Consulting Inc. now owns 92 shares of the medical equipment provider’s stock worth $25,000 after acquiring an additional 86 shares during the last quarter. Imprint Wealth LLC bought a new position in shares of ResMed in the third quarter worth about $26,000. WFA of San Diego LLC bought a new position in shares of ResMed in the second quarter worth about $26,000. ORG Partners LLC lifted its position in shares of ResMed by 181.6% during the fourth quarter. ORG Partners LLC now owns 107 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 69 shares in the last quarter. Finally, Sunbelt Securities Inc. acquired a new position in shares of ResMed during the third quarter worth approximately $31,000. Institutional investors and hedge funds own 54.98% of the company’s stock.

ResMed Stock Down 1.0%

ResMed stock opened at $219.73 on Friday. The company’s 50 day simple moving average is $237.17 and its 200 day simple moving average is $248.86. ResMed Inc. has a fifty-two week low of $216.68 and a fifty-two week high of $293.81. The firm has a market capitalization of $32.01 billion, a price-to-earnings ratio of 21.73, a PEG ratio of 1.46 and a beta of 0.93. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.06 and a quick ratio of 2.32.

ResMed (NYSE:RMD) last issued its earnings results on Friday, January 30th. The medical equipment provider reported $2.81 EPS for the quarter, beating the consensus estimate of $2.68 by $0.13. The firm had revenue of $1.42 billion during the quarter, compared to the consensus estimate of $1.40 billion. ResMed had a net margin of 27.53% and a return on equity of 25.20%. The business’s quarterly revenue was up 11.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.43 earnings per share. As a group, sell-side analysts anticipate that ResMed Inc. will post 11.05 EPS for the current year.

ResMed Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, March 19th. Stockholders of record on Thursday, February 12th were issued a $0.60 dividend. The ex-dividend date of this dividend was Thursday, February 12th. This represents a $2.40 annualized dividend and a dividend yield of 1.1%. ResMed’s payout ratio is 23.74%.

Insiders Place Their Bets

In other ResMed news, CEO Michael J. Farrell sold 4,991 shares of ResMed stock in a transaction dated Tuesday, April 7th. The stock was sold at an average price of $225.50, for a total transaction of $1,125,470.50. Following the transaction, the chief executive officer directly owned 466,223 shares in the company, valued at approximately $105,133,286.50. The trade was a 1.06% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Peter C. Farrell sold 2,000 shares of the business’s stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $225.00, for a total value of $450,000.00. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 21,023 shares of company stock valued at $5,230,857. 0.65% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of brokerages recently weighed in on RMD. Royal Bank Of Canada raised their price target on shares of ResMed from $311.00 to $314.00 and gave the company an “outperform” rating in a report on Friday, January 30th. KeyCorp reaffirmed an “overweight” rating and set a $302.00 price objective on shares of ResMed in a report on Friday, January 30th. Robert W. Baird set a $281.00 price objective on ResMed in a research report on Friday, January 30th. JPMorgan Chase & Co. assumed coverage on ResMed in a research note on Wednesday, April 15th. They issued an “overweight” rating for the company. Finally, Wall Street Zen lowered ResMed from a “buy” rating to a “hold” rating in a research note on Saturday, March 14th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $295.64.

ResMed Company Profile

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.